Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems
Rhea-AI Summary
Sight Sciences (Nasdaq: SGHT) announced that Aetna’s updated Glaucoma Surgery Policy for commercial plans now recognizes the OMNI Surgical System and SION Surgical Instrument as medically necessary for treating mild-to-moderate open-angle glaucoma when specified clinical criteria are met.
The policy, retroactive to July 14, 2026, establishes coverage of Sight Sciences’ implant-free, minimally invasive glaucoma surgery technologies, including ab interno canaloplasty (e.g., OMNI) and adult goniotomy (e.g., SION). Aetna covers approximately 25 million total commercial lives in the U.S.
Positive
- Aetna coverage for OMNI and SION as medically necessary for mild-to-moderate open-angle glaucoma
- Coverage effective retroactively to July 14, 2026 under Aetna’s Glaucoma Surgery Policy
- Access to Aetna’s ~25 million total commercial covered lives in the United States
- Recognition of implant-free MIGS procedures, including ab interno canaloplasty and adult goniotomy
Negative
- None.
Market Reaction – SGHT
Following this news, SGHT has declined 8.29%, reflecting a notable negative market reaction. Our momentum scanner has triggered 20 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $5.09. Trading volume is elevated at 2.5x the average, suggesting increased selling activity.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 22 | Earnings date notice | Neutral | -6.6% | Announced second-quarter results timing and post-market reporting schedule |
| May 06 | Earnings report | Positive | +23.0% | Reported first-quarter results and raised full-year revenue guidance |
| Apr 29 | Investor conferences | Neutral | +3.0% | Scheduled presentations at two healthcare investor conferences |
| Apr 22 | Sustainability report | Neutral | +1.2% | Published third annual sustainability report covering 2023–2025 activities |
| Apr 21 | Earnings date notice | Neutral | +0.5% | Announced first-quarter results timing and post-market reporting schedule |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Substantive positive announcements were followed by positive reactions, while an earnings-date notice was followed by a negative reaction.
Key Terms
minimally invasive glaucoma surgery medical
ab interno canaloplasty medical
goniotomy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eyecare and improve patients’ lives, today announced that Aetna, Inc.’s (Aetna) updated Glaucoma Surgery Policy for its commercial plans now recognizes the OMNI® Surgical System (OMNI) and the SION® Surgical Instrument (SION) as medically necessary for the treatment of mild-to-moderate open-angle glaucoma when specified clinical criteria are met, establishing coverage of Sight Sciences’ interventional glaucoma technologies.
“We are pleased that Aetna’s rigorous clinical review resulted in expanded coverage for implant-free, minimally invasive glaucoma surgery (MIGS) procedures, including OMNI and SION. This reinforces the important role these technologies can play in the glaucoma treatment paradigm,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. “With this coverage milestone, broad payer access has been established for canaloplasty and goniotomy enabled by the OMNI Surgical System and SION Surgical Instrument across all major national payers. We appreciate our surgeon customers, key opinion leaders, state and national societies, Aetna medical directors, and our market access team whose engagement helped advance medically necessary access to MIGS care for glaucoma patients.”
Aetna’s Glaucoma Surgery Policy recognizes multiple implant-free glaucoma procedures as medically necessary, including ab interno canaloplasty (e.g., OMNI) and adult goniotomy (e.g., SION), for mild-to-moderate open-angle glaucoma when specified clinical criteria are met. This coverage policy is retroactive to July 14, 2026. Aetna is one of the largest health insurers in the United States, with approximately 25 million total commercial covered lives.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease.
Visit www.sightsciences.com for more information.
Sight Sciences, TearCare, and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI, SION, and the Sight Sciences logo are trademarks of Sight Sciences registered in the United States, European Union and other territories. TruSync is a trademark of Sight Sciences.
Aetna is a registered trademark of Aetna Inc.
© 2026 Sight Sciences. All rights reserved.
Forward-Looking Statements
This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results. These forward-looking statements include, but are not limited to, statements concerning the following: Aetna members’ future ability to access OMNI and SION technologies and obtain coverage for procedures using the OMNI and SION technologies, when deemed medically necessary, and the continuation of existing coverage policies by payers. These forward-looking statements are subject to and involve numerous risks, uncertainties and assumptions, including those discussed under the caption “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings, and you should not place undue reliance on these statements. These cautionary statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Media contact:
pr@sightsciences.com
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
